CD47 and lymphoma: In addition, it is verified that tumor cells overexpress CD47 to escape from immune surveillance in various malignant tumors such as leukemia, lymphoma, breast and colon cancer, and antagonism CD47 has significant anti-tumor effects (Horrigan, 2017; Lian et al., 2019; Hu et al., 2020).